RNXT

CEO Presentation: Shaun Bagai, CEO of RenovoRx, will present at the LD Micro Invitational XV on April 10, 2025, discussing the company's commercialization efforts for its FDA-cleared RenovoCath device and updates on initial revenues and the Phase III TIGeR-PaC clinical trial.

RenovoCath Overview: RenovoCath is a novel drug-delivery device designed for targeted oncology therapies, currently under investigation for treating locally advanced pancreatic cancer using the proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts for traders to stay updated on stock market movements.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories from Benzinga reporters.

Financial Performance and Growth Expectations: RenovoRx reported initial revenues of approximately $43,000 from its RenovoCath device in Q4 2024, with expectations for sequential revenue growth throughout 2025, supported by new customer orders and reorders. The company has a cash position of $7.2 million and raised an additional $12.1 million in February 2025 to fund operations and scale revenue.

Clinical Trial Progress: The ongoing Phase III TIGeR-PaC clinical trial is on track for full enrollment in 2025, with 90 patients randomized as of March 2025. A second interim analysis is anticipated following the occurrence of the 52nd event, expected in Q2 2025, which will inform the continuation of the study based on recommendations from the Data Monitoring Committee.

Insider Trading Activity: Laurence Marton, a director at $RNXT, purchased 12,050 shares for approximately $10,218, increasing his holdings by 35.8%, with insiders making three purchases and no sales in the past six months.

Institutional Investor Movements: In the latest quarter, nine institutional investors increased their positions in $RNXT stock while four reduced theirs, indicating varied investor sentiment towards the company.

Earnings Release: $RNXT is set to announce its quarterly earnings on April 1st, with analysts predicting no revenue and a loss of $0.11 per share.

Institutional Activity: In the latest quarter, 9 institutional investors increased their holdings in $RNXT while 8 reduced theirs, indicating mixed investor sentiment.

TAMP Therapy Platform: RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) therapy platform shows promise for targeted chemotherapy delivery, potentially reducing toxicities compared to traditional intravenous methods, as evidenced by new human pharmacokinetic data presented at the Society of Surgical Oncology Annual Meeting.

Clinical Trial Insights: The ongoing Phase III TIGeR-PaC clinical trial indicates that localized intra-arterial delivery of gemcitabine using the RenovoCath device results in lower systemic drug levels and may decrease chemotherapy-related side effects for patients with locally advanced pancreatic cancer.

RenovoRx's Commercialization Efforts: Shaun Bagai, CEO of RenovoRx, will discuss the company's progress in commercializing its FDA-cleared RenovoCath device, including initial revenue generation and new orders from cancer centers during a fireside chat on April 3, 2025.

TIGeR-PaC Clinical Trial Update: The ongoing Phase III TIGeR-PaC clinical trial is evaluating the intra-arterial delivery of gemcitabine via the RenovoCath device for treating locally advanced pancreatic cancer, with interim analyses showing positive recommendations for continuation of the study.

New Clinical Data Presentation: RenovoRx announced the presentation of new pre-clinical data supporting its Trans-Arterial Micro-Perfusion (TAMP™) therapy platform at the Society of Surgical Oncology 2025 Annual Meeting, highlighting its potential for targeted delivery in treating locally advanced pancreatic cancer.

Ongoing Clinical Trial: The ongoing Phase III TIGeR-PaC clinical trial is evaluating the intra-arterial delivery of gemcitabine using the TAMP platform, with patient enrollment expected to complete by mid-2025 and interim analyses indicating continued study viability.

RenovoCath Commercialization Progress: RenovoRx, Inc. is experiencing growth in its commercial strategy for the RenovoCath device, receiving new purchase orders from high-volume National Cancer Institute-designated centers and generating initial revenues expected this quarter.

Market Potential and Future Plans: The company estimates a potential market of up to $400 million annually for RenovoCath as a standalone device, with plans to expand its customer base and explore further revenue-generating opportunities either independently or through partnerships.

Funding Announcement: RenovoRx, Inc. has successfully closed a $12.1 million public offering of common stock, which will be used to strengthen its balance sheet and support ongoing clinical trials and commercialization efforts for its FDA-cleared RenovoCath delivery system.

Clinical Development Plans: The company aims to achieve significant milestones in 2025, including the first sales revenue from RenovoCath and completion of enrollment in its pivotal Phase III TIGeR-PaC clinical trial for treating locally advanced pancreatic cancer.

Public Offering Announcement: RenovoRx, Inc. has priced a public offering of 11,523,810 shares of common stock at $1.05 per share, aiming to raise approximately $12.1 million for working capital and corporate purposes, including advancing its Phase III TIGeR-PaC study.

Company Overview: RenovoRx specializes in targeted oncology therapies, utilizing its FDA-cleared RenovoCath delivery platform for precise drug delivery, particularly in treating locally advanced pancreatic cancer, with ongoing commercialization efforts and initial purchase orders received for its devices.

Public Offering Announcement: RenovoRx Inc. has priced a public offering of approximately 11.52 million shares at $1.05 each, expecting to raise about $12.1 million before expenses, with the offering closing on February 10, 2025.

Use of Proceeds: The funds will be allocated for working capital, advancing its Phase III TIGeR-PaC study, and enhancing commercial sales and marketing efforts for its device, RenovoCath.

Public Offering Details: RenovoRx has priced its public offering of 11.52 million shares at $1.05 each, aiming for gross proceeds of $12.1 million, with the closing expected on February 10, 2025.

Use of Proceeds: The company plans to utilize the net proceeds for working capital and corporate purposes, including advancing its Phase III TIGeR-PaC study and developing the RenovoCath device.

Stock Offering Details: A deal has been priced below the last closing price of $1.46, with Titan Partners serving as the sole book running manager for the offering.

Investment Insights: TipRanks offers a Smart Score tool to help investors identify top-performing stocks and compare their picks with recommendations from Wall Street analysts.

Public Offering Announcement: RenovoRx, Inc. has initiated an underwritten public offering of its common stock or pre-funded warrants, with proceeds intended for working capital and the advancement of its Phase III TIGeR-PaC study and commercial activities for its FDA-cleared RenovoCath delivery platform.

Company Overview: RenovoRx specializes in developing targeted oncology therapies using its patented Trans-Arterial Micro-Perfusion (TAMP™) technology, which aims to enhance the delivery of chemotherapy while minimizing systemic toxicity, and is currently investigating the use of gemcitabine for treating locally advanced pancreatic cancer.

Public Offering Announcement: RenovoRx, Inc. has initiated an underwritten public offering of its common stock or pre-funded warrants, with proceeds intended for working capital and advancing its Phase III TIGeR-PaC study and marketing efforts for its FDA-cleared RenovoCath delivery platform.

Company Overview and Future Plans: RenovoRx is focused on developing targeted oncology therapies using its patented TAMP™ technology and has received Orphan Drug Designation for its gemcitabine treatment for pancreatic cancer, while also exploring commercialization strategies for its RenovoCath device.

Upcoming ASCO GI Symposium: The 2025 ASCO Gastrointestinal Cancers Symposium will take place from January 23-25 in San Francisco, focusing on the rising cancer rates among individuals under 50, particularly gastrointestinal cancers like colorectal and pancreatic cancers.

Oncolytics Biotech's Pelareorep Presentation: Oncolytics Biotech Inc. will present promising data on its immunotherapy, pelareorep, which has shown significant response rates in relapsed anal cancer and potential for improving outcomes in pancreatic cancer when combined with standard chemotherapy regimens.

Upcoming ASCO GI Symposium: The 2025 ASCO Gastrointestinal Cancers Symposium will take place from January 23-25 in San Francisco, focusing on the rising cancer rates among individuals under 50, particularly gastrointestinal cancers like colorectal and pancreatic cancer.

Oncolytics Biotech's Pelareorep Presentation: Oncolytics Biotech Inc. will present promising data on its immunotherapy pelareorep at the symposium, showcasing its potential to improve treatment outcomes for patients with relapsed anal and metastatic pancreatic cancers, highlighting significant response rates compared to historical averages.

Intellectual Property and Clinical Trials: RenovoRx is advancing its targeted oncology therapies using the Trans-Arterial Micro-Perfusion (TAMP) platform, holding a strong intellectual property position with multiple patents filed globally. The company is preparing for commercial plans and clinical trial advancements in 2025, including the pivotal Phase III TIGeR-PaC trial for treating locally advanced pancreatic cancer.

RenovoCath Device Commercialization: The FDA-cleared RenovoCath device, designed for precise drug delivery, has received its first purchase orders as RenovoRx moves forward with commercialization efforts. The device aims to enhance treatment efficacy while minimizing toxicities compared to traditional systemic therapies.

Recent Advancements in Cancer Treatment: Innovative therapies, including a novel immunotherapy leading to complete remission for a stage 4 breast cancer patient and the first personalized mRNA cancer vaccine in Europe, highlight significant progress in oncology research and treatment options.

Oncolytics Biotech's Progress: Oncolytics Biotech Inc. reports promising results from its BRACELET-1 study in breast cancer and ongoing advancements in gastrointestinal cancer treatments, with plans for further data presentations and potential commercialization opportunities in 2025.